FDA approves gene-editing therapy for sickle cell disease

The FDA approved gene-editing therapy Casgevy to treat sickle cell disease. Developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), the one-time treatment harnesses gene editing advancements.
Vertex CEO Dr. Reshma Kewalramani says the approach involves extracting a patient’s stem cells, correcting the defect in those cells using CRISPR gene editing tools, then re-infusing the edited cells into the patient – relieving painful symptoms.
Patients who undergo this $2.2 million procedure may eliminate painful sickle cell crises called VOC’s. Kewalramani contrasts the cost against the $4-6 million lifetime price tag for conventional sickle cell management.
#youtube #genetics #yahoofinance

About Yahoo Finance:

Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.

– Get the latest news and data at finance.yahoo.com

– Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)

– Follow Yahoo Finance on social:

X: http://twitter.com/YahooFinance
Instagram: https://www.instagram.com/yahoofinance/?hl=en
TikTok: https://www.tiktok.com/@yahoofinance?lang=en
Facebook: https://www.facebook.com/yahoofinance/
LinkedIn: https://www.linkedin.com/company/yahoo-finance